- Home
- CYRX vs SLN Comparison
CYRX vs SLN Comparison
Compare CYRX & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- SLN
- Stock Information
- Founded
- CYRX 1999
- SLN 1994
- Country
- CYRX United States
- SLN United Kingdom
- Employees
- CYRX N/A
- SLN N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- CYRX Health Care
- SLN Health Care
- Exchange
- CYRX Nasdaq
- SLN Nasdaq
- Market Cap
- CYRX 381.6M
- SLN 352.2M
- IPO Year
- CYRX N/A
- SLN N/A
- Fundamental
- Price
- CYRX $7.86
- SLN $6.88
- Analyst Decision
- CYRX Buy
- SLN Strong Buy
- Analyst Count
- CYRX 7
- SLN 4
- Target Price
- CYRX $13.14
- SLN $61.50
- AVG Volume (30 Days)
- CYRX 446.9K
- SLN 691.1K
- Earning Date
- CYRX 11-07-2024
- SLN 11-14-2024
- Dividend Yield
- CYRX N/A
- SLN N/A
- EPS Growth
- CYRX N/A
- SLN N/A
- EPS
- CYRX N/A
- SLN N/A
- Revenue
- CYRX $226,113,000.00
- SLN $21,773,221.00
- Revenue This Year
- CYRX N/A
- SLN N/A
- Revenue Next Year
- CYRX $7.92
- SLN $104.98
- P/E Ratio
- CYRX N/A
- SLN N/A
- Revenue Growth
- CYRX N/A
- SLN N/A
- 52 Week Low
- CYRX $5.32
- SLN $5.81
- 52 Week High
- CYRX $20.11
- SLN $27.72
- Technical
- Relative Strength Index (RSI)
- CYRX 53.97
- SLN 32.78
- Support Level
- CYRX $7.44
- SLN $5.96
- Resistance Level
- CYRX $8.37
- SLN $8.88
- Average True Range (ATR)
- CYRX 0.63
- SLN 0.73
- MACD
- CYRX 0.02
- SLN 0.27
- Stochastic Oscillator
- CYRX 51.66
- SLN 33.77
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.